These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29194765)

  • 1. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
    Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
    J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
    Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
    BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
    Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vinblastine for treatment of canine mast cell tumors.
    Rassnick KM; Bailey DB; Flory AB; Balkman CE; Kiselow MA; Intile JL; Autio K
    J Vet Intern Med; 2008; 22(6):1390-6. PubMed ID: 19000249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
    Halsey CHC; Thamm DH; Weishaar KM; Burton JH; Charles JB; Gustafson DL; Avery AC; Ehrhart EJ
    Vet Pathol; 2017 May; 54(3):387-394. PubMed ID: 28129097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
    Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
    BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH; Mauldin EA; Vail DM
    J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
    Thamm DH; Turek MM; Vail DM
    J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
    Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
    Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case report of feline mast cell tumour with intertumoral heterogeneity: Identification of secondary mutations c.998G>C and c.2383G>C in KIT after resistance to toceranib.
    Tani H; Hifumi T; Ito K; Kuramoto T; Miyoshi N; Fujiki M; Nakayama T
    Vet Med Sci; 2024 Sep; 10(5):e70003. PubMed ID: 39177283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
    Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
    J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation and methylation status of KIT and TP
    Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J
    Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer drug approved for dogs.
    J Am Vet Med Assoc; 2009 Jul; 235(2):139. PubMed ID: 19610240
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
    Gustafson TL; Biller B
    J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.